About Us
About DUALSAVE-FGS
DUALSAVE-FGS is a partnership of nine African and European institutions aiming at developing a cost-effective joint screening method for Female Genital Schistosomiasis and cervical cancer.
The partners will clinically validate the Spectral Artificial Vision (SAVE) colposcope, invented and developed by our partner QCELL, a biophotonics imaging company based in Greece.
SAVE is a low-cost, hand-held digital colposcope, integrating the most advanced spectral imaging and machine learning technologies with the possibility for large-scale implementation.
SAVE is capable of identifying cervical (pre-)cancer and hopefully FGS, instantly, and without being in contact with the patient. DUALSAVE-FGS will also provide virtual training of frontline primary health care professionals and gynaecologists in FGS diagnosis and management. A social science study will be carried out, to learn how procedures are perceived by patients and health professional.
Project Areas
South Africa | Eswatini | Mozambique
Our Mission
To train and prepare health professionals in the diagnosis of Female Genital Schistosomiasis (FGS) and to develop and clinically test a diagnostic imaging tool that fulfils both performance requirements and socio-economic criteria for roll-out in schistosomiasis endemic African countries.
Our Vision
To reform current diagnostic and screening practices for cervical cancer and Female Genital Schistosomiasis (FGS), train health professionals, and adapt spectral imaging technology for improved precision, accessibility and acceptability.
Our Ambition
To substantially reduce morbidity and mortality associated with Female Genital Schistosomiasis (FGS) and cervical cancer by deploying our imaging technology and training in the diagnosis and screening of women in schistosomiasis endemic countries.